Education
About Us
Working with TipRanks
Follow Us
JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
2126 Stock Chart & Stats
HK$2.50
-HK$0.02(-1.56%)
At close: 4:00 PM EST
HK$2.50
-HK$0.02(-1.56%)
Day’s Range― - ―
52-Week RangeHK$1.26 - HK$6.44
Previous CloseN/A
Volume104.00K
Average Volume (3M)2.67M
Market Cap
HK$907.91M
Enterprise ValueHK$564.41M
Total Cash (Recent Filing)HK$647.04M
Total Debt (Recent Filing)HK$372.46M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding416,473,240
10 Day Avg. Volume1,852,649
30 Day Avg. Volume2,667,300
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.43
Price to Sales (P/S)3.14
P/FCF Ratio-1.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthReported multi-year revenue growth indicates expanding commercial traction and/or progress in clinical asset value. Durable revenue growth supports continued R&D investment, strengthens negotiating position for partnerships, and underpins long-term development funding needs amid rising cell-therapy demand.
Strong Cash Position & Low LeverageA significant cash buffer and conservative leverage provide runway for expensive clinical programs and initial commercialization investments. This financial flexibility reduces near-term refinancing risk, limits forced dilution, and supports strategic option execution over the coming quarters.
Focus On CAR-T / Cell TherapiesOperating in CAR-T and cell therapy addresses large unmet oncology needs where structural demand and high barriers to entry persist. Specialized technology and clinical expertise create durable competitive advantages and make the company an attractive partner or acquirer as therapies mature.
Bears Say
Persistent UnprofitabilityOngoing negative net income and EBIT margins limit internal capital generation and weaken returns to shareholders. Persistent losses constrain the company's ability to self-fund expansion and increase dependency on external financing, raising execution and dilution risk over the medium term.
Negative Operating & Free Cash FlowConsistently negative operating and free cash flow mean the business is not yet cash-generative and relies on financing activity to sustain operations. This creates vulnerability if capital markets tighten and can delay commercialization timelines or force unfavorable funding terms.
High Losses Despite Margin ImprovementMarginal gross-margin improvements have been insufficient to offset scale-up costs, R&D, and SG&A, indicating operational inefficiencies. Without structural cost control or faster revenue conversion, profitability remains distant and growth may require continued external support.
JW (Cayman) Therapeutics Co. Ltd. News
2126 FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was HK$1.26 and its highest was HK$6.44 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is HK$907.91M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Mar 25, 2026 which is in 31 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Aug 27, 2025. The company reported -HK$0.724 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.724.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,473,240 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -HK$0.724 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.794%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in HK:2126
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.33%
12-Months-Change
Fundamentals
Return on Equity
-51.56%
Trailing 12-Months
Asset Growth
-26.90%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, focuses on developing, manufacturing, and commercializing cell-based immunotherapies for hematological cancers and solid tumors. The company offers cell-based immunotherapies, including CAR-T treatments, which is a treatment method that uses human immune cells to fight cancer. Its lead product candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of a range of hematological cancers. The company's pipeline products include JWCAR129, an autologous CAR-T therapy for the treatment of multiple myeloma; JWATM204, a TCR T-cell therapy candidate for the treatment of HCC; and JWATM203, an autologous T-cell receptor mimic T-cell therapy targeting alpha-fetoprotein for the treatment of hepatocellular carcinoma. JW (Cayman) Therapeutics Co. Ltd was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Lepu Biopharma Co. Ltd. Class H
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Options Prices
Currently, No data available
---